BBIO
Income statement / Annual
Last year (2023), BridgeBio Pharma, Inc.'s total revenue was $9.30 M,
a decrease of 88.02% from the previous year.
In 2023, BridgeBio Pharma, Inc.'s net income was -$643.20 M.
See BridgeBio Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$9.30 M
|
$77.65 M
|
$69.72 M
|
$8.25 M
|
$40.56 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.45 M |
$3.43 M |
$3.11 M |
$3.09 M |
$2.50 M |
$0.00 |
$260,000.00 |
| Gross Profit |
$6.86 M |
$74.21 M |
$66.60 M |
$5.16 M |
$38.06 M |
$0.00 |
-$260,000.00 |
| Gross Profit Ratio |
0.74 |
0.96 |
0.96 |
0.63 |
0.94 |
0 |
0 |
| Research and Development
Expenses |
$455.71 M
|
$402.90 M
|
$454.14 M
|
$337.05 M
|
$209.95 M
|
$140.07 M
|
$30.56 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$150.59 M
|
$143.19 M
|
$192.21 M
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Other Expenses |
$7.93 M |
$100.45 M |
$35.82 M |
$1.63 M |
-$1.21 M |
-$1.29 M |
$0.00 |
| Operating Expenses |
$614.23 M |
$546.09 M |
$646.35 M |
$482.73 M |
$304.30 M |
$183.66 M |
$43.86 M |
| Cost And Expenses |
$616.67 M |
$546.09 M |
$646.35 M |
$482.73 M |
$306.80 M |
$183.66 M |
$43.86 M |
| Interest Income |
$18.04 M |
$7.54 M |
$1.13 M |
$4.02 M |
$8.92 M |
$2.00 M |
$39,000.00 |
| Interest Expense |
$81.29 M |
$80.44 M |
$46.78 M |
$36.66 M |
$8.77 M |
$2.55 M |
$13,000.00 |
| Depreciation &
Amortization |
$6.49 M
|
$6.77 M
|
$5.84 M
|
$3.09 M
|
$859,001.00
|
$245,000.00
|
$260,000.00
|
| EBITDA |
-$565.47 M
|
-$397.44 M
|
-$533.83 M
|
-$465.75 M
|
-$279.82 M
|
-$183.42 M
|
-$43.56 M
|
| EBITDA Ratio |
-60.78 |
-4.55 |
-7.74 |
-56.84 |
-6.89 |
0 |
0 |
| Operating Income Ratio
|
-65.29
|
-6.08
|
-8.32
|
-57.52
|
-6.56
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$45.88 M
|
$27.55 M
|
-$9.82 M
|
-$31.01 M
|
-$22.35 M
|
$14.21 M
|
$26,000.00
|
| Income Before Tax |
-$653.25 M |
-$484.65 M |
-$586.45 M |
-$505.49 M |
-$288.59 M |
-$169.45 M |
-$43.83 M |
| Income Before Tax Ratio
|
-70.22
|
-6.24
|
-8.41
|
-61.28
|
-7.12
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$9.31 M |
$52.84 M |
-$21.56 M |
-$28.15 M |
$16.76 M |
-$13.49 M |
| Net Income |
-$643.20 M |
-$493.96 M |
-$639.30 M |
-$483.93 M |
-$260.44 M |
-$130.75 M |
-$30.57 M |
| Net Income Ratio |
-69.14 |
-6.36 |
-9.17 |
-58.66 |
-6.42 |
0 |
0 |
| EPS |
-3.95 |
-3.35 |
-4.43 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| EPS Diluted |
-3.95 |
-3.35 |
-4.43 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| Weighted Average Shares
Out |
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Weighted Average Shares
Out Diluted |
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Link |
|
|
|
|
|
|
|
